A phase II study of Pmab+IRI for mCRC pts with wildKRAS, resistant to fluoropyrimidine, ox-aliplatin and IRI（OGSG1001）
研究実績
検索結果：
すべて の研究実績
FU, IRI, OX不応KRAS野生型mCRCに対するIRI+Panitumumab 療法の日本人データ （OGSG1001）
Phase II feasibility study of adjuvant s-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 1002)
Stage III胃癌に対する術後補助化学療法としての6か月間の ドセタキセル+S-1投与の検討（OGSG1002）
FU、プラチナ療法不応の進行再発食道癌に対するDOC療法とPTX療法の比較第II相試験（OGSG1201）
Randomized phase II study of CPT-11 versus PTX: +/- S1 in advanced gastric cancer refractory to S1 or S1 + platinum (OGSG0701)
Three-year outcomes of a phase Ⅱ study of adjuvant chemotherapy with S-1 plus docetaxel for stage Ⅲ gastric cancer after curative D2 gastrectomy
A Phase I/II Trial of Radiotherapy Concurrent with TS-1 Plus Cisplatin in Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group（OGSG1205）
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer ; OGSG1101, HGCSG1102, T-CORE1101 Intergroup study (HERBIS-1 trial)
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer ; OGSG1101, HGCSG1102, T-CORE1101 Intergroup study (HERBIS-1 trial)